S-1/A: Kairos Pharma Eyes NYSE American Listing with $6.2 Million IPO

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline and list its common stock on the NYSE American under the symbol KAPA.

Summary

• Kairos Pharma, a clinical-stage biopharmaceutical company, is planning an initial public offering of 1,550,000 shares of common stock, expecting an initial public offering price of $4.00 per share.
• The company aims to list its common stock on the NYSE American under the symbol KAPA, contingent upon approval of its listing application.
• Kairos Pharma intends to use the net proceeds of approximately $5.6 million to fund clinical trials of its product candidates, including ENV 105, preclinical product candidates including KROS 101, potential acquisition or in-licensing activities, and for working capital and general corporate purposes.
• The company's pipeline includes seven drug candidates targeting various cancers, including prostate, lung, breast cancer and glioblastoma.
• Kairos Pharma has licensed key patents from Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• The company's lead drug candidate, ENV 105, is currently in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer.
• The company is an emerging growth company and a smaller reporting company, which allows it to take advantage of reduced public company reporting requirements.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report on the company's financial statements as of and for the years ended December 31, 2022 and 2023, indicating substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is advancing its pipeline and targeting significant market opportunities, it also faces substantial financial challenges, including a going concern warning and the need for additional funding. The company's reliance on third parties and the inherent risks of drug development further temper the outlook.

Positives

• The company has a diversified pipeline of seven drug candidates targeting various cancers.
• The company has licensed key patents from Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• A previous Phase 2 trial of ENV 105 in prostate cancer showed a 62% clinical benefit rate in a heavily pre-treated population.
• The company is an emerging growth company and a smaller reporting company, allowing for reduced reporting requirements.

Negatives

• The company has incurred significant losses since its inception and expects to incur losses over the next several years.
• The company has limited operating history and no products approved for commercial sale.
• The company requires substantial additional funding to meet its financial needs and pursue its business objectives.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report on the company's financial statements as of and for the years ended December 31, 2022 and 2023, indicating substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's success is heavily dependent on the success of its initial drug candidates, which are still under clinical development.
• The company faces substantial competition from large, well-funded, and experienced competitors.
• The company is relying exclusively on the skills and expertise of its management team, not all of whom will devote all of their time to managing the company.
• The company's exclusive licensing rights to its intellectual property are subject to agreements with third parties and may be terminated.
• The company has limited experience designing and implementing clinical trials and has never conducted pivotal clinical trials.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, expensive, and inherently unpredictable.
• The trading price of the company's common stock may be volatile, and investors could lose all or part of their investment.
• The closing of the offering is contingent on the company obtaining listing on the NYSE American.

Future Outlook

The company expects to continue to incur significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through clinical development, seeks regulatory approval, and operates as a public company.

Management Comments

• Our goal is to unlock the power of the immune system on the two most pervasive problems in cancer treatment: resistance to therapy and immune suppression by cancer.
• We believe this road will lead to major improvement in the quality of life of cancer patients and will transform patient outcomes.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products, particularly in the immuno-oncology segment. Kairos Pharma faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic and research institutions.

Comparison to Industry Standards

• The global prostate cancer therapeutics market was valued at USD 7.9 billion and at USD 1.7 billion for EGFR mutant non-small cell lung cancer.
• Androgen targeted therapy accounts for USD 15 billion in sales in 8 primary markets.
• The global cancer drug spending is expected to reach $311.2 billion by 2026 driven largely by the growth of immuno-oncology.
• Global immunotherapy market estimates show significant compound growth with sales expectations ranging from $94.7-$126.9 billion by 2026, exhibiting a CAGR of up to 20.2% from 2020.
• T cell therapy market size is expected to be around $20.8 billion by 2030 from its value of $4.9 billion in 2021 with a CAGR of 20.4% during the forecast period 2022-2030.
• The global small-molecule cancer therapies market size was valued at $175.3 billion in 2021 and is expected to have a CAGR of 5.44% from 2022 to 2030.
• The global peptide therapeutics market size was estimated at $39.3 billion in 2021 and is expected to reach $42.1 billion in 2022.
• The cancer cachexia therapeutics market is estimated to reach above $1 billion in the U.S. alone.

Related Party Transactions

• Shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company $0.01 million, all of which was outstanding at December 31, 2021.
• Two officers and shareholders agreed to convert the $0.004 million due to them into 1,664 shares of the Companys common stock, effective upon the closing of the Companys IPO.
• The Company borrowed $0.07 million from three of its officers. The loans accrue interest at 7.5% per annum, are unsecured, and are due in April 2025.

Stakeholder Impact

• Shareholders will experience immediate dilution of their investment.
• The company's success will depend on its ability to attract, retain, and motivate qualified personnel.
• The company's ability to commercialize its product candidates will depend on their acceptance by physicians, patients, and third-party payors.

Next Steps

• Complete Phase 1 and Phase 2 clinical trials of ENV 105.
• Complete pre-IND studies for KROS 101.
• Initiate a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.
• Continue to advance the pipeline of immunotherapeutics for clinical trials.
• Seek regulatory approval for product candidates.
• Establish sales, marketing, and distribution capabilities or enter into agreements with third parties to commercialize product candidates.

Key Dates

Keywords

Kairos Pharma, biopharmaceutical, cancer therapeutics, ENV 105, KROS 101, clinical trials, IPO, NYSE American, drug resistance, immune suppression